Extrafine single-inhaler triple therapy with BDP/FF/GB is effective for improving health-related quality of life and lung function in COPD.

Clinical benefits of the interleukin-33 inhibitor were observed in a broad population, including both former and current smokers, regardless of eosinophil levels. Topline results were announced from ...

Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...

When living with chronic obstructive pulmonary disease (COPD), you can help prevent lung infections by quitting smoking and avoiding irritants such as secondhand smoke and strong scents. It’s ...

According to the World Health Organisation, chronic obstructive pulmonary disease is the fourth-leading cause of death globally. Yet even with this statistic, COPD continues to be extensively ...

Background: Diagnosing acute exacerbation of chronic obstructive pulmonary disease (AECOPD) remains challenging in clinical practice. Computed tomography (CT) plays a great role in characterizing and ...

Brensocatib, a DPP1 inhibitor, is the first FDA-approved therapy for non-cystic fibrosis bronchiectasis, showing significant clinical and structural benefits. The ASPEN trial demonstrated that ...

WILLIAMSPORT, Pa. — November is Chronic Obstructive Pulmonary Disease or COPD Awareness Month. The American Lung Association says COPD affects more than 11 million adults and accounts for hundreds of ...

Queen's University Belfast-led research reports on a multicenter trial finding no significant reduction in pulmonary exacerbations with hypertonic saline or carbocisteine over 52 weeks among adults ...

Bronchiectasis guidelines are inconsistent with regard to the effectiveness of mucoactive agents, and their use varies geographically. Large trials are needed to assess safety and effectiveness. For ...